LIQUIDIA CORP
A clinical-stage biopharmaceutical company that is focused on developing products based on its proprietary virosome technology platform.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Liquidia Corp's stock with a target price of $24.44, indicating potential growth.
Financial Health
Liquidia Corp is performing well with good revenue and cash flow, showing strong profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Upcoming trial readouts and regulatory milestones can materially affect valuation, though outcomes are uncertain and may cause share volatility.
Delivery technology edge
The proprietary PRINT particle-engineering platform aims to improve inhaled drug delivery and consistency; technology progress and IP protection matter.
Commercial and partners
Partnerships and manufacturing scale-up influence commercial prospects, but market uptake, pricing and competition remain material risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
